Dynavax Technologies | DVAX - Ebitda


Dynavax Technologies reported $35.53M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
AbbVie USD 4.34B 56M Jun/2025
Adma Biologics USD 58.74M 14.75M Sep/2025
Amgen USD 5.91B 2.31B Sep/2025
AstraZeneca USD 4.96B 127M Jun/2025
Biogen USD 1.01B 456.5M Jun/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Dynavax Technologies USD 35.53M 10.9M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Neurocrine Biosciences USD 246.7M 93.8M Sep/2025
Novartis USD 5.88B 290M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
TG Therapeutics USD 37.7M 25.41M Jun/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025